"ALL-MED" Specjalistyczna Opieka Medyczna, Medyczny Instytut Badawczy
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jutel, Marek
NCT04542057 / 2020-002069-32: A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Recruiting
3
800
Europe, Canada, US
Ensifentrine, Placebo
Verona Pharma plc, Iqvia Pty Ltd
Chronic Obstructive Pulmonary Disease
01/22
02/22
NCT04206605 / 2019-001703-20: A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Recruiting
3
75
Europe, Canada, US
Lanadelumab, SHP643, DX-2930, TAK-743, Placebo
Shire, Takeda Development Center Americas, Inc.
Angioedema
03/23
03/23
Rhapsody, NCT04881461: A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis

Recruiting
3
440
Europe, RoW
5-grass mix SLIT-drops, SLIToneULTRA, Placebo
ALK-Abelló A/S, Syneos Health
Allergy
09/23
09/23
NCT04719832 / 2020-003632-25: Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Recruiting
3
375
Europe, US, RoW
GSK3511294 (Depemokimab), Placebo
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
02/24
02/24
Jutal, Marek
NCT04542057 / 2020-002069-32: A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Recruiting
3
800
Europe, Canada, US
Ensifentrine, Placebo
Verona Pharma plc, Iqvia Pty Ltd
Chronic Obstructive Pulmonary Disease
01/22
02/22

Download Options